Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0015674 (
chronic fatigue syndrome
)
2,978
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Composite ferrate(VI) solution (
CFS
) with improved stability was successfully prepared in this study. The stability of Fe(VI) increased from hours for potassium ferrate at pH 9-10 to 16d for 1 mmol L(-1) Fe(VI) in
CFS
at 25 degrees C, decomposing 24%. The Fe(VI) was more stable at low concentration (1 mmol L(-1)) than that at high concentration (10 mmol L(-1)). The degradation of the azo dye reactive brilliant red X-3B (X-3B) by
CFS
was investigated. The results showed that pH, initial dye concentration and
CFS
dosage affected the degradation efficiency. For 0.08 mmol L(-1) X-3B simulate wastewater, the optimal pH and
CFS
dosage were 8.4 and 25 mg L(-1) (as K(2)FeO(4)), and about 99% X-3B was decolorized after 20 min under this conditions. The color decay was considerably faster than the decrease in COD and
TOC
, which was attributed to the ease of chromophore destruction. Compared with the decolorization, the removal percentage of COD and
TOC
were 42% and 9% after 60 min, respectively. The Fe(VI) and ClO(-) were contained in
CFS
, which have synergetic effect for the degradation of X-3B. Additionally, phthalic acid and muconic acid were identified as intermediates by GC/MS, which was in accordance with the lowered pH with the reaction time. The complete mineralization of X-3B cannot be achieved under the oxidation by
CFS
. And a tentative pathway for the oxidative degradation of X-3B was postulated.
...
PMID:Degradation of azo dye active brilliant red X-3B by composite ferrate solution. 1855 98